- Evaxion Biotech ( EVAX ) Pantherna Therapeutics reported preclinical data related to their mRNA vaccine for tumors.
- The companies said preclinical data showed that tumor neoantigens identified by Evaxion's AI platform PIONEER drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna's lipid nanoparticle mRNA platform (PTX?LNP, PTXmRNA).
- "The data provide further evidence that immunogenic sequences identified by Evaxion’s AI platforms are able to drive a relevant immune response on multiple vaccine platforms, including mRNA. This opens up many opportunities in our current and future immuno-oncology and infectious disease programs," said Evaxion Chief Scientific Officer Birgitte Rønø.
- The companies noted that will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion's AI platforms.
- EVAX +25.56% to $2.26 premarket Feb. 8
For further details see:
Evaxion stock surges ~25% on preclinical data for mRNA vaccine for cancer